---
title: Survival with chronic myeloid leukaemia after failing milestones
date: '2023-09-19'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37726340/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20230920181035&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: Therapy after failing response milestones in CML is controversial. Risks
  associated with comorbidities, drug toxicities or transplantation may preclude switching
  to another tyrosine kinase inhibitor (TKI) or other treatments. No information on
  long-term survival of failing patients is available. To systematically analyse survival
  after reaching, or not reaching, response milestones, 1342 patients from CML-study
  IV with newly diagnosed CML in chronic phase and regular molecular tests ...
disable_comments: true
---
Therapy after failing response milestones in CML is controversial. Risks associated with comorbidities, drug toxicities or transplantation may preclude switching to another tyrosine kinase inhibitor (TKI) or other treatments. No information on long-term survival of failing patients is available. To systematically analyse survival after reaching, or not reaching, response milestones, 1342 patients from CML-study IV with newly diagnosed CML in chronic phase and regular molecular tests ...